Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research report released on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $695.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals’ FY2025 earnings at $26.38 EPS. Several other research […]
Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research report released on Tuesday morning, Marketbeat reports. The firm issued an overweight rating and a $695.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals’ FY2025 earnings at $26.38 EPS. Several other research […]
